Vinati Organics Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹13.8K Cr
Vinati Organics projects a 20% CAGR in revenue over the next three years. Vinati Organics projects a 20% CAGR in revenue over the next 3 years, driven by leadership in ATBS, steady butyl phenol performance, and strong antioxidants growth.
From Vinati Organics's Q4 FY25 earnings-call transcript · updated 26 Aug 2026.
Price
₹1,333
Market Cap
₹13.8K Cr
P/E Ratio
27.6
How does Vinati Organics rank in Chemicals & Petrochemicals?
Compare Vinati Organics against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Vinati Organics — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹611 Cr, net profit ₹138 Cr.
Full financials →📊 Revenue & Sales Performance
- →Vinati Organics projects a 20% CAGR in revenue over the next three years.
- →Continued robust growth expected in ATBS driven by volume expansion and rising demand from oil recovery and water treatment.
- →Antioxidants (AO) business to see strong momentum with capacity utilization expected to increase from ~50% to 90% over two years.
- →Butyl phenols anticipated to grow steadily, with FY26 revenue expected between INR800-850 crores from antioxidants alone.
- →VOPL (Veeral Organic) subsidiary aims for ~INR100 crores revenue in FY26, ramping up product commercialization.
- →New products under development (anisole derivatives, 4-MAP, TAA, PTAP) to diversify portfolio and fuel growth.
- →Brownfield expansions for ATBS capacity planned in two phases, with phase 1 operational by June 2025.
- →Overall growth supported by strategic capex (~INR360 crores in FY26), innovation, and operational efficiencies.
📈 Profitability & Margins
- →Vinati Organics projects a 20% CAGR in revenue over the next 3 years, driven by leadership in ATBS, steady butyl phenol performance, and strong antioxidants growth.
- →EBITDA margins are expected to sustain at 26%-27% over the long term (3 to 5 years), excluding other income.
- →Antioxidants (AO) business revenue grew 70% in FY '25 and is anticipated to continue robust growth in FY '26, supported by new product development.
- →ATBS segment showed 30% growth in FY '25, with continued strong demand and expected double-digit volume growth in FY '26.
- →Revenue from butyl phenols and antioxidants combined is expected to grow from INR600 crores in FY '25 to INR800-850 crores in FY '26.
- →Veeral Organic’s (VOPL) revenue is expected around INR100 crores in FY '26, with capacity utilization improving.
- →Continued investments in capex (~INR360 crores in FY '26) and R&D underpin future growth and operational efficiency.
🏗️ Capital Expenditure Plans
- →FY'25 capex was approx INR400 crores, focused on capacity enhancements, new products, and operational scalability including investments in Vinati Organic Products Limited (VOPL).
- →ATBS capacity expansion scheduled for completion by June 2025, increasing capacity by about 25-30% in Phase 1, followed by a second phase a year later. Total Brownfield capex for ATBS expansion budgeted at INR300 crores.
- →VOPL capex total INR500 crores; about INR250 crores done, balance pending. Products including MEHQ, Guaiacol, TAA, PTAP, Anisole, and 4-Methoxy Acetophenone will be commercialized.
- →FY'26 capex marked at approx INR360 crores to continue expansion, innovation, and operational efficiency.
- →Plans for the next leg of capex based on success of 3-4 new products currently in R&D.
- →Focus on vertical and horizontal integration to add products and diversify portfolio.
💰 Fundraising & Capital Structure
- →The transcript does not mention any current or planned fundraising through debt or equity.
- →Capital expenditure (capex) plans for FY '26 are around INR 360 crores, focused on expansion, innovation, and operational efficiency.
- →The company is funding capex primarily through internal accruals, as there is no specific reference to raising funds via equity or debt in the call.
- →No mention of new debt or equity issuance for funding the ongoing ATBS expansion, VOPL capex, or other projects.
- →Management focuses on revenue growth, operational efficiencies, and sustained profitability rather than external fundraising.
📋 Order Book & Pipeline
- →The company is currently oversold in the ATBS segment.
- →There is a backlog of pending orders for ATBS.
- →The new capacity coming in Phase 1 of the ATBS expansion is expected to be filled immediately upon commissioning due to the existing order book.
- →Demand remains strong, driven by the oil and gas sector and enhanced oil recovery applications.
- →Overall, the company has good visibility and client commitments for increased capacity.
Key Metrics
Frequently Asked Questions
What were Vinati Organics Q4 FY25 results?
Vinati Organics projects a 20% CAGR in revenue over the next three years. Vinati Organics projects a 20% CAGR in revenue over the next 3 years, driven by leadership in ATBS, steady butyl phenol performance, and strong antioxidants growth.
What is Vinati Organics share price analysis?
Vinati Organics currently shows a neutral. The stock trades at a P/E of 27.6 with a market cap of ₹13,781 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vinati Organics planning capital expenditure?
FY'25 capex was approx INR400 crores, focused on capacity enhancements, new products, and operational scalability including investments in Vinati Organic Products Limited (VOPL). - ATBS capacity expansion scheduled for completion by June 2025, increasing capacity by about 25-30% in Phase 1, followed by a second phase a year later.
Keep Vinati Organics on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.